Mural Oncology plc (NASDAQ:MURA) Short Interest Update

Mural Oncology plc (NASDAQ:MURA) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 396,800 shares, a decline of 25.2% from the January 15th total of 530,200 shares. Currently, 2.6% of the company’s shares are sold short. Based on an average trading volume of 206,900 shares, the short-interest ratio is currently 1.9 days.

Mural Oncology Stock Performance

NASDAQ:MURA traded up $0.02 on Friday, reaching $4.28. The company’s stock had a trading volume of 18,599 shares, compared to its average volume of 196,209. Mural Oncology has a 1-year low of $2.87 and a 1-year high of $5.62. The firm has a market cap of $72.76 million, a PE ratio of -0.47 and a beta of 3.90. The business’s 50-day moving average price is $3.69 and its two-hundred day moving average price is $3.51.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC boosted its position in shares of Mural Oncology by 2.6% during the third quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock worth $595,000 after buying an additional 4,731 shares during the period. FMR LLC boosted its position in shares of Mural Oncology by 124.7% during the third quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after buying an additional 11,423 shares during the period. Commerce Bank acquired a new position in shares of Mural Oncology during the third quarter worth about $39,000. Renaissance Technologies LLC boosted its position in shares of Mural Oncology by 17.4% during the fourth quarter. Renaissance Technologies LLC now owns 238,465 shares of the company’s stock worth $768,000 after buying an additional 35,403 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Mural Oncology during the fourth quarter worth about $129,000. 80.21% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Mural Oncology in a research note on Monday, November 11th.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.